The company was founded in 1988 and listed on the Shenzhen Stock Exchange in June 2008. It is a leading domestic blood products enterprise integrating raw plasma collection, research and development, production and sales of blood products. The company's main business is the production and sale of blood products. The company's main products are human blood albumin, intravenous human immunoglobulin, specific immunoglobulins, coagulation factor products, etc. Shanghai Laishi is a “Shanghai Foreign-Invested Advanced Technology Enterprise” and a “High-tech Enterprise” certified by the Shanghai Science and Technology Commission. It has successively won the Forbes “2015 World's Most Innovative Companies List”, Forbes China's “Top 10 Most Innovative Companies in Asia 2015”, and “Top 20 Most Competitive Pharmaceutical Listed Companies”.
No Data
No Data